YntraDose (yttrium-90 microspheres) / BetaGlue Therapeutics - LARVOL DELTA

One Month Preclinical Safety and Efficacy Evaluation of a Yttrium-90 Resin Microsphere Glue Formulation in the Oncopig® Pancreatic Cancer Model (SIO 2026) - "This work confirms the ability of the Oncopig pancreatic cancer model to provide easily identifiable tumor targets for laparoscopic injection of radiotherapies that are suitable for chronic PET-CT follow up. The results of this study confirm safety and feasibility of intratumor injection of YntraDose in the Oncopig pancreatic cancer model, helping advance translation of this novel therapeutic approach into clinical practice."

Preclinical • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC (clinicaltrials.gov) - P=N/A | N=10 | Recruiting | Sponsor: BetaGlue Therapeutics SpA | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) (The Manila Times) - "The clinical study is expected to begin enrolling patients in early 2026, with preliminary results expected by the end of the year. This early feasibility clinical investigation aims to assess the safety, usability and feasibility of YntraDose administration in patients with unresectable LA-PDAC, a disease with limited effective treatment options and a significant unmet medical need."

New trial • Pancreatic Ductal Adenocarcinoma